All News
#ACR23 Abstr#0548 Is there a risk prediction tool to help exclude non-immune pathology for Rheumatologists with newly referred ANA+? 3-yr data showed 3 BL markers: IFN score B, criteria No & FH of RMD had 98% specificity. Cd help inform early Tx trials in High Risk @RheumNowNews https://t.co/DCAg4EwM9d
Md Yuzaiful Md Yusof ( View Tweet)
TNF AND IL17 was equally effective in Axial SpA!
#ACR23 #Reviewcourse https://t.co/oofQkvsJ3f
Nouf Al hemmadi ( View Tweet)
Need to improve our conversations with young adults on methotrexate about alcohol and sexual activity. They are often uncomfortable and/or dishonest about telling. Great work from @McMasterU by undergrad Matthew Sholdice #transition @drgrainnemurray #ACR23 https://t.co/wwyZLQVA51
Catherine Hill CatherineL_Hill ( View Tweet)
Extrahepatic manifestations of #hepatitisC #ACR23 https://t.co/sb0AQofkvt
dr hanady manasfi hanadymanasfi ( View Tweet)
I would like to participate in a prospective trial for prevention on RA by pizza consumption. #ACR23 https://t.co/Y96xFolUgM
Adela Castro AdelaCastro222 ( View Tweet)
#ACR23 #ReviewCourse - By Dr. Francesco Boin. Systemic Sclerosis Screening for Organ Involvement. This slide is a true "take home slide" @ACRheum #ACRambassador https://t.co/4FVYWJjHyV
Anne Troldborg ( View Tweet)
Or to quote the great Murray Urowitz @UHN "a #lupus pregnancy has four trimesters"! #ACR23 https://t.co/Iw2S81tiTH
Ian N Bruce ( View Tweet)
✅ Question to YOU attending #ACR23 ➡️ We're almost at the end of 2023 ⌛and many great #lupus data are being presented at @ACRheum Convergence 2023 in San Diego 👍 What would YOU update/change 🔄 regarding the management of #lupus in 2024 compared to 2023? 🧭 https://t.co/xpSXjuDjyr
Laurent ARNAUD ( View Tweet)
Real-life data about the PEXIVAS reduced-dose glucocorticoid regimen in #granulomatosis with polyangiitis and microscopic #polyangiitis (Abstract 0725 https://t.co/7x34Hr0OMP)
@TerrierBen
#ACR23
#ACRambassador https://t.co/D8UfZvXQCl
Alessia Alunno ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on SpA Update: Radiographic and Non-Radiographic AS - Dr. Alexis Ogdie
1. Workup of inflammatory back pain: History, exam, CRP, HLA-B27, SI joint films, MRI pelvis (STIR images, no need for contrast). Response to NSAIDs not actually… https://t.co/M0W6UNsPxF https://t.co/7k3xl1RXZz
Paul Sufka, MD psufka ( View Tweet)
ABS0524:
⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA
➡️active dz, HLAB27+, 2 or more AAU flares
⭐️CZP reduced AAU flare rate by 87%
#ACR23 @RheumNow
#ACRBest https://t.co/rW0N18agMO
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on Update on Relapsing Polychondritis - Dr. Marcela Ferrada
1. Be aware of common/uncommon manifestations (see slide). Affects more than just the ear!!!
2. Collagen II antibodies: not really sensitive or specific for diagnosis. Biopsy… https://t.co/f5xGtcMzk3 https://t.co/xVigSabXDb
Paul Sufka, MD psufka ( View Tweet)
Are we tapering steroids too rapidly? Real world experience: steroid tapering in severe #AAV based on #PEXIVAS protocol noted higher rates of dz progression, relapse, ESRD, death. Risk greatest when creatinine > 300umol/L and w/RTX induction #Plenary1 #ACR23 Abst#0725 #ACrBest https://t.co/Rtv7vkzUUD
TheDaoIndex KDAO2011 ( View Tweet)
ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno
Adela Castro AdelaCastro222 ( View Tweet)
🔥 Absolute masterclass @philseo in the Clinical Year in Review #ACR23
➡️ Certain subpopulations have lower risk of AE with Tofacitinib
➡️ Knee OA 📈 75% by 2050
➡️ Exciting novel approaches in Rx of IA in development
➡️Better clinical trial endpoints needed for SLE https://t.co/5cjbZLPsCM
Caoilfhionn Connolly ( View Tweet)
#Denosumab and what to do IF you stop it
#ACR23 #osteoporosis #Bisphosphonate #CTX https://t.co/qwdQQjJJlb
Dr Gurdeep S Dulay ( View Tweet)
Efficacy and Safety of Targeted Therapies in #VEXAS Syndrome: Retrospective Study from the French VEXAS Group :)
#ACR23 late breaking poster - the figure says it all
https://t.co/qahDDPLois https://t.co/ueb4aG8t77
Latika LatikaGupta_ ( View Tweet)
ABS0538:
⭐️Characteristics of difficult-to-treat (D2T) axSpA pts:
➡️HLAB27(-)
➡️smokers
➡️shorter symptom duration
➡️more enthesitis
➡️IBD
➡️concomitant NSAID use
➡️Co-morbidities (HTN, HLD, fibro, depress/anxiety)
#ACR23 @RheumNow https://t.co/TqEVBeaJpb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Yield of repeated assessments of SpA features in patients with CBP suspected of axSpA was modest for the increase of new definite axSpA diagnosis at 2y. Sacroilitis on MRI, good response to NSAIDs at BL most predictive of axSpA, ML Marques #ACR23 @RheumNow https://t.co/LQ5llML11M https://t.co/PYcCDypI7c
Dr. Antoni Chan ( View Tweet)
What a great pleasure to meet with the most amazing @RheumNow team on site at #ACR23 so glad to meet Shannon, Mitzi, John @Yuz6Yusof @Janetbirdope and looking forward to sharing the learnings from the conference https://t.co/ovXXLxDLKW
Dr. Antoni Chan ( View Tweet)